Corteva ( CTVA) said the quarter was affected by seasonal timing shifts that moved some deliveries into the third quarter of ...

Management believes that exclusion of these items assists in providing a more complete understanding of the Company’s underlying results and trends, and management uses these measures along with the ...

Narrowing full‑year fiscal 2026 Adjusted EBITDA guidance to $400–$420 million, reflecting approximately $11 million of temporary impacts from the Calvert City startup delay and recent weather-related ...

Revenue 1 decreased 3% from prior year to $2.9 billion for the quarter and decreased 2% to $9.7 billion for the year due to the sale of TRANZACT ...

Columbia Sportswear Company (NASDAQ: COLM, the "Company"), a multi-brand global leading innovator in outdoor, active and ...

Revenue1 decreased 3% from prior year to $2.9 billion for the quarter and decreased 2% to $9.7 billion for the year due to the sale of TRANZACTOrganic Revenue growth of 6% for the quarter and 5% for ...

SHELTON, CT. (February 3, 2026) – Hubbell Incorporated (NYSE: HUBB) today reported operating results for the fourth quarter and full year ended December 31, 2025.

Strong growth and real-world data set the stage for U.S. market expansion OssDsign AB (publ) announces that the year-end report for 2025 is now available as a PDF on the company's website ...

EQS-News: AT&S Austria Technologie & Systemtechnik AG / Key word(s): Quarterly / Interim Statement AT&S records positive net profit again in the third quarter 03.02.2026 / 07:00 CET/CEST The issuer is ...

TransDigm Group Incorporated (NYSE: TDG), a leading global designer, producer and supplier of highly engineered aircraft components, ...

Vitrolife AB (VTRLY) reports strong organic growth in the Americas and APAC regions despite currency headwinds impacting overall performance.

Altimmune, Inc. closed a $75 million direct offering to fund Phase 3 pemvidutide trials for MASH. Learn more about ALT stock here.